Guest guest Posted February 9, 2008 Report Share Posted February 9, 2008 well, I took the antibacterial eye drops and rills for 5 days like a good little girl and it made the fog(infection in the aqueous humor fluid) much worse not to mention my migraines,ect. a little better now. I went to follow up with a doctor who than gave me a prescription for...., you guessed it. more antibiotics. pretty insane when you have better luck doctoring yourself and practiceing advoidance than from a ER or doctors office. whats bad is I still have blocked tear ducts and it well probibly happen again with the next round of cns infection. > > well, kist thought I'd share that my left eye swelled up like a > bullfrog. eyelid was full of fluid. > they found blocked tear duct was causeing bacteria to back flow. > I've read about this with saecoidosis patients where they have to put a > spring/shunt in to open it up or something. gee, I wonder what the > blockage is? been fighting the severe migrines with this so I'm kind of > guessing it came from my head somewhere. given antibacterial eye drops > and antibiotics, to sick last night to tell if antib's were helping or > worse. cant see to read the kind but made sure no mold driven, no corn > additives so well see. keeping close eye on it. well, others are > because I cant see it. hopefully weather will cooperate next week to > get to a specialest. > Quote Link to comment Share on other sites More sharing options...
Guest guest Posted February 10, 2008 Report Share Posted February 10, 2008 Have you tried n-acetyl-carnosine eye drops? They inhibit AGEs and have been shown to improve vision - might be worth trying? Even plain oral l-carnosine may help, I'd guess. But not anywhere near as dramatically. The n-acetyl-carnosine eye drops are available commercially from a number of companies. Plain L-Carnosine is available in health food stores as pills. See the refs below. Taurine may also help protect vision. Taurine is very inexpensive. Could post refs on that if you want them. On 2/10/08, who <jeaninem660@...> wrote: > > well, I took the antibacterial eye drops and rills for 5 days like a > good little girl and it made the fog(infection in the aqueous humor > fluid) much worse not to mention my migraines,ect. a little better > now. I went to follow up with a doctor who than gave me a > prescription for...., you guessed it. more antibiotics. > pretty insane when you have better luck doctoring yourself and > practiceing advoidance than from a ER or doctors office. > whats bad is I still have blocked tear ducts and it well probibly > happen again with the next round of cns infection. > > > > > > well, kist thought I'd share that my left eye swelled up like a > > bullfrog. eyelid was full of fluid. > > they found blocked tear duct was causeing bacteria to back flow. > > I've read about this with saecoidosis patients where they have to > put a > > spring/shunt in to open it up or something. gee, I wonder what the > > blockage is? been fighting the severe migrines with this so I'm > kind of > > guessing it came from my head somewhere. given antibacterial eye > drops > > and antibiotics, to sick last night to tell if antib's were helping > or > > worse. cant see to read the kind but made sure no mold driven, no > corn > > additives so well see. keeping close eye on it. well, others are > > because I cant see it. hopefully weather will cooperate next week > to > > get to a specialest. > > > > * *Drugs R D. <javascript:AL_get(this, 'jour', 'Drugs R D.');>2005;6(6):345-69. > Related Articles<http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed & DbFrom=pubmed & Cmd=Li\ nk & LinkName=pubmed_pubmed & LinkReadableName=Related%20Articles & IdsFromResult=1627\ 4259 & ordinalpos=1 & itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_\ RVAbstract>, > Links <javascript:PopUpMenu2_Set(Menu16274259);> > > *Analysis of lipid peroxidation and electron microscopic survey of > maturation stages during human cataractogenesis: pharmacokinetic assay of > Can-C N-acetylcarnosine prodrug lubricant eye drops for cataract prevention. > * > > *Babizhayev MA*<http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed & Cmd=Search & Term=%22Babizh\ ayev%20MA%22%5BAuthor%5D & itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.\ Pubmed_RVAbstract> > . > > Innovative Vision Products Inc., County of New Castle, Delaware 19810, > USA. markbabizhayev@... > > Morphological and biophysical techniques described in this study have > shown that membrane derangement occurs in human cataractous lenses. The data > suggest that these disruptions were globules, vacuoles, multilamellar > membranes and clusters of highly undulating membranes. Deleterious > structural damage of the lens fibre cell plasma membranes serve as the > primary light-scattering centres that cause the observed lens opacity. > Nuclear cataract, a major cause of loss of lens transparency in the aging > human, has been thought to be associated with oxidative damage, particularly > at the site of the nuclear plasma membrane. Phospholipid molecules modified > by oxygen accumulate in the lipid bilayer, change its geometry and impair > lipid-lipid and protein-lipid interactions in lenticular fibre membranes. > Lipid peroxidation (LPO) is a causative and pathogenic factor in cataract. > Increased concentrations of primary molecular LPO products (diene > conjugates, lipid hydroperoxides, oxy-derivatives of phospholipid fatty > acids) and end-fluorescent LPO products have been detected in the lipid > moieties of aqueous humour samples and human lenses obtained from patients > with senile and complicated cataracts as compared with normal donors. In the > present study, a rapid and simple high-performance liquid chromatographic > (HPLC) assay for determination of imidazole-containing dipeptides in the > aqueous humour of the eye was developed. The method was applied to determine > the pharmacokinetic parameters and the time-course of N-acetylcarnosine and > L-carnosine-related product in the eye, following a single dosage of topical > ocular administration of peptide. Utilising data from pharmacokinetic > studies and the specific purity of the N-acetylcarnosine (NAC) ingredient as > a source of the pharmacological principle L-carnosine, we have created an > ophthalmic time-release prodrug form including the US FDA-approved > carboxymethylcellulose lubricant and other essential ingredients (Can-C, > private label Nu-Eyes). This formulation increases the intraocular > absorption of L-carnosine in the aqueous humour and optimises its specific > antioxidant activity in vivo while reducing the toxic effects of lipid > peroxides on the crystalline lens. L-carnosine that enters the aqueous > humour can accumulate in the lens tissue for a reasonable period of time. > The presence of L-carnosine in transparent crystalline lenses during normal > aging was detected and its concentration in this case was about 25 microM. > At different stages of cataract development, the level of L-carnosine > drastically decreased, reaching about 5 microM in ripe human cataracts. > However, administration of pure L-carnosine (1% solution) to the rabbit eye > (instillation or subconjunctival injection) does not lead to accumulation of > this natural compound in the aqueous humour at the time level over 30 > minutes at a concentration exceeding that in placebo-treated matched eyes, > and its effective concentration is exhausted more rapidly. Use of NAC > prodrug eye drops optimises the clinical effects of L-carnosine in the > treatment of ophthalmic disorders (such as prevention and reversal of > cataracts in human and animal [canine] eyes). The data provided predict a > clinical effect with NAC ophthalmic prodrug, and show that the magnitude and > duration of this effect are directly related to the bioavailability of > L-carnosine released from NAC in the aqueous humour of the anterior eye > segment. The ophthalmic NAC drug shows promise in the treatment of a range > of ophthalmic disorders that have a component of oxidative stress in their > pathogenesis (including cataract, glaucoma, dry eye, vitreous floaters, > inflammatory disorders, and corneal, retinal and systemic diseases [such as > diabetes mellitus and its ophthalmic complications]). There is a need for > further and better collaboration between Innovative Vision Products' > cataract control and ophthalmic services, improved education of people > affected by cataract, a commitment that N-acetylcarnosine eye drops will be > the preferred treatment before orthodox cataract surgery is attempted, and > consideration of outcomes and a possible role of the NAC drug cataract > treatment as source of referral for orthodox surgical, ophthalmic and > optometric services. > > Publication Types: > > - Research Support, Non-U.S. Gov't <javascript:AL_get(this, 'ptyp', > 'Research Support, Non-U.S. Gov\'t');> > > > PMID: 16274259 [PubMed - indexed for MEDLINE] > ------------------------------ > *2: *Rejuvenation Res. <javascript:AL_get(this, 'jour', 'Rejuvenation > Res.');> 2004 Fall;7(3):186-98. > Related Articles<http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed & DbFrom=pubmed & Cmd=Li\ nk & LinkName=pubmed_pubmed & LinkReadableName=Related%20Articles & IdsFromResult=1558\ 8519 & ordinalpos=2 & itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_\ RVAbstract>, > Links <javascript:PopUpMenu2_Set(Menu15588519);> > [image: Click here to read]<http://www.ncbi.nlm.nih.gov/entrez/utils/fref.fcgi?PrId=3043 & itool=Abstrac\ t-def & uid=15588519 & db=pubmed & url=http://dx.doi.org/10.1089/rej.2004.7.186> > *Rejuvenation of visual functions in older adult drivers and drivers with > cataract during a short-term administration of N-acetylcarnosine lubricant > eye drops.* > > *Babizhayev MA*<http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed & Cmd=Search & Term=%22Babizh\ ayev%20MA%22%5BAuthor%5D & itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.\ Pubmed_RVAbstract> > . > > Innovative Vision Products, Inc. Moscow Division, Ivanovskaya 20, Suite > 74, Moscow 127434, Russian Federation. markbabizhayev@... > > The purpose of this study was to examine using the original halometer > glare test of the type of visual impairment mediated by the increased glare > sensitivity (halos) and associated with poorer visual function in both the > better and worse eyes of older adult drivers and older drivers with > cataract. The clinically validated (by Innovative Vision Products Inc.) > formula of 1% N-acetylcarnosine (NAC) lubricant eye drops were applied > topically to the eyes of older drivers to reduce glare disability and > improve distance acuities for driving. This was a randomized, double-blind, > placebo-controlled study. The examined subjects consisted of 65 older adults > with cataract in one or both eyes, and 72 adult drivers who did not have > cataract in either eye. In the control group, comparison with baseline > values showed some variability of data in gradual worsening of glare > sensitivity at red and green targets and minimal VA changes over 4 months. > In the NAC-treated group, 4-month follow-up generally showed an improvement > in VA and a significant improvement in glare sensitivity at red and green > targets was documented in worse and better eyes using a critical cut point > halometer score for driving. The NAC-treated eyes had statistically > significant difference in VA, glare sensitivity compared with the control > group ( p < 0.001) at 4-month timepoint of treatment, as supported by the > overall t-test results of the ratio of the follow-up data to the baseline > values. Tolerability of NAC eyedrops was good in almost all patients, with > no reports of ocular or systemic adverse effects. It would be advisable for > traffic safety if a Halometer glare sensitivity test was implemented for > vehicles and/or was regularly added to the requirements for a driver's > licence. The results of this study provide a substantial basis for further > evaluation of NAC in the treatment and prevention of vision impairment in > the older population of drivers for legal driving. The developed ophthalmic > drug NAC formula showed potential for the non-surgical treatment of > age-related cataracts. > > Publication Types: > > - Clinical Trial <javascript:AL_get(this, 'ptyp', 'Clinical > Trial');> > - Randomized Controlled Trial <javascript:AL_get(this, 'ptyp', > 'Randomized Controlled Trial');> > - Research Support, Non-U.S. Gov't <javascript:AL_get(this, 'ptyp', > 'Research Support, Non-U.S. Gov\'t');> > > > PMID: 15588519 [PubMed - indexed for MEDLINE] > ------------------------------ > *3: *Exp Eye Res. <javascript:AL_get(this, 'jour', 'Exp Eye Res.');> 2004 > Apr;78(4):815-22. > Related Articles<http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed & DbFrom=pubmed & Cmd=Li\ nk & LinkName=pubmed_pubmed & LinkReadableName=Related%20Articles & IdsFromResult=1503\ 7116 & ordinalpos=3 & itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_\ RVAbstract>, > Links <javascript:PopUpMenu2_Set(Menu15037116);> > [image: Click here to read]<http://www.ncbi.nlm.nih.gov/entrez/utils/fref.fcgi?PrId=3048 & itool=Abstrac\ t-def & uid=15037116 & db=pubmed & url=http://linkinghub.elsevier.com/retrieve/pii/S00\ 14483503003683> > *Mechanism of a model dipeptide transport across blood-ocular barriers > following systemic administration.* > > *Atluri H*<http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed & Cmd=Search & Term=%22Atluri%\ 20H%22%5BAuthor%5D & itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed\ _RVAbstract>, > *Anand BS*<http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed & Cmd=Search & Term=%22Anand%\ 20BS%22%5BAuthor%5D & itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubme\ d_RVAbstract>, > *Patel J*<http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed & Cmd=Search & Term=%22Patel%2\ 0J%22%5BAuthor%5D & itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_\ RVAbstract>, > *Mitra AK*<http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed & Cmd=Search & Term=%22Mitra%\ 20AK%22%5BAuthor%5D & itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubme\ d_RVAbstract> > . > > Division of Pharmaceutical Sciences, School of Pharmacy, University of > Missouri-Kansas City, 5005 Rockhill Road, Kansas City, MO 64112-2499, USA. > > The purposes of this study were to provide functional evidence for the > presence of a peptide transporter on blood-ocular barriers and to elucidate > the mechanism of a dipeptide transport across these barriers following > systemic administration. Glycylsarcosine was chosen as a model dipeptide and > [(3)H] glycylsarcosine was administered through the marginal ear vein of New > Zealand white rabbits. At the end of an experimental period, vitreous humor, > retina and aqueous humor were collected. Time dependent uptake of > glycylsarcosine into ocular tissues was studied at 5, 10, 15 and 30 min. > Competitive inhibition studies were performed by intravenous administration > of [(3)H] glycylsarcosine with and without various inhibitors. > Concentration-dependent ocular uptake of glycylsarcosine was carried out by > administration of various concentrations of unlabelled glycylsarcosine > spiked with a fixed amount of [(3)H] glycylsarcosine. Time-dependent uptake > of glycylsarcosine into vitreous humor, retina and aqueous humor for a > period of 30 min following systemic administration was linear. Ocular uptake > of glycylsarcosine was inhibited by peptide transporter substrates such as > dipeptides (glycylproline and carnosine) and captopril but not by > non-substrates such as amino acids. Concentration-dependent self-inhibition > of glycylsarcosine ocular uptake was also observed. The results indicate > that model dipeptide is transported across blood-ocular barriers via a > carrier-mediated process. In conclusion, an oligopeptide transport system is > involved in the transport of glycylsarcosine across blood-ocular barriers. > This information may be utilized to design transporter/receptor targeted > drug delivery systems for efficient ocular uptake from systemic > administration. > > Publication Types: > > - Research Support, U.S. Gov't, P.H.S. <javascript:AL_get(this, > 'ptyp', 'Research Support, U.S. Gov\'t, P.H.S.');> > > > PMID: 15037116 [PubMed - indexed for MEDLINE] > ------------------------------ > *4: *Drugs R D. <javascript:AL_get(this, 'jour', 'Drugs R D.');>2002;3(2):87-103. > Related Articles<http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed & DbFrom=pubmed & Cmd=Li\ nk & LinkName=pubmed_pubmed & LinkReadableName=Related%20Articles & IdsFromResult=1200\ 1824 & ordinalpos=4 & itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_\ RVAbstract>, > Links <javascript:PopUpMenu2_Set(Menu12001824);> > > *Efficacy of N-acetylcarnosine in the treatment of cataracts.* > > *Babizhayev MA*<http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed & Cmd=Search & Term=%22Babizh\ ayev%20MA%22%5BAuthor%5D & itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.\ Pubmed_RVAbstract>, > *Deyev AI*<http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed & Cmd=Search & Term=%22Deyev%\ 20AI%22%5BAuthor%5D & itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubme\ d_RVAbstract>, > *Yermakova VN*<http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed & Cmd=Search & Term=%22Yermak\ ova%20VN%22%5BAuthor%5D & itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.P\ ubmed_RVAbstract>, > *Semiletov YA*<http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed & Cmd=Search & Term=%22Semile\ tov%20YA%22%5BAuthor%5D & itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.P\ ubmed_RVAbstract>, > *Davydova NG*<http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed & Cmd=Search & Term=%22Davydo\ va%20NG%22%5BAuthor%5D & itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pu\ bmed_RVAbstract>, > *Doroshenko VS*<http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed & Cmd=Search & Term=%22Dorosh\ enko%20VS%22%5BAuthor%5D & itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.\ Pubmed_RVAbstract>, > *Zhukotskii AV*<http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed & Cmd=Search & Term=%22Zhukot\ skii%20AV%22%5BAuthor%5D & itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.\ Pubmed_RVAbstract>, > *Goldman IM*<http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed & Cmd=Search & Term=%22Goldma\ n%20IM%22%5BAuthor%5D & itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pub\ med_RVAbstract> > . > > Innovative Vision Products, Inc., County of Newcastle, Delaware, USA. > markbabizhayev@... > > PURPOSE: To evaluate the effects of 1% N-acetylcarnosine (NAC) solution on > lens clarity over 6 and 24 months in patients with cataracts. TRIAL DESIGN: > Randomised, placebo-controlled study. PARTICIPANTS: 49 subjects (76 affected > eyes) with an average age of 65.3 +/- 7.0 years with a diagnosis of senile > cataract with minimum to advanced opacification in various lens layers. > METHODS: 26 patients (41 eyes) were allocated to topical NAC 1% eyedrops > twice daily. The control group consisted of 13 patients (21 eyes) who > received placebo eyedrops and 10 patients (14 eyes) who did not receive > eyedrops. MAIN OUTCOME MEASURES: All patients were evaluated at entry and > followed up every 2 months for a 6-month period (trial 1), or at 6-month > intervals for a 2-year period (trial 2), for best-corrected visual acuity > and glare testing. In addition, cataract was measured using > stereocinematographic slit-images and retro-illumination examination of the > lens. Digital analysis of lens images displayed light scattering and > absorbing centres in two- and three-dimensional scales. RESULTS: The overall > intra-reader reproducibility of cataract measurements (image analysis) was > 0.830, and glare testing 0.998. After 6 months, 90% of NAC-treated eyes > showed improvement in best corrected visual acuity (7 to 100%) and 88.9%showed a 27 to 100% improvement in glare sensitivity. Topographic studies > indicated fewer areas of posterior subcapsular lens opacity and 41.5% of > treated eyes had improvement in image analysis characteristics. The overall > ratios of image analysis characteristics at 6 months compared with baseline > measures were 1.04 and 0.86 for the control and NAC-treated group, > respectively (p < 0.001). The apparent benefits of treatment were > sustained after 24 months' treatment. No treated eyes demonstrated worsening > of vision. The overall visual outcome in the control group showed > significant worsening after 24 months in comparison with both baseline and > the 6-month follow-up examination. The overall clinical results observed in > the NAC-treated group by the 24-month period of examination differed > significantly (p < 0.001) from the control group in the eyes with > cortical, posterior subcapsular, nuclear or combined lens opacities. > Tolerability of NAC eyedrops was good in almost all patients, with no > reports of ocular or systemic adverse effects. CONCLUSION: Topical NAC shows > potential for the treatment and prevention of cataracts. > > Publication Types: > > - Clinical Trial <javascript:AL_get(this, 'ptyp', 'Clinical > Trial');> > - Randomized Controlled Trial <javascript:AL_get(this, 'ptyp', > 'Randomized Controlled Trial');> > - Research Support, Non-U.S. Gov't <javascript:AL_get(this, 'ptyp', > 'Research Support, Non-U.S. Gov\'t');> > > > PMID: 12001824 [PubMed - indexed for MEDLINE] > ------------------------------ > *5: *Biochemistry (Mosc). <javascript:AL_get(this, 'jour', 'Biochemistry > (Mosc).');> 2000 May;65(5):588-98. > Related Articles<http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed & DbFrom=pubmed & Cmd=Li\ nk & LinkName=pubmed_pubmed & LinkReadableName=Related%20Articles & IdsFromResult=1085\ 1037 & ordinalpos=5 & itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_\ RVAbstract>, > Links <javascript:PopUpMenu2_Set(Menu10851037);> > > *The natural histidine-containing dipeptide Nalpha-acetylcarnosine as an > antioxidant for ophthalmic use.* > > *Babizhayev MA*<http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed & Cmd=Search & Term=%22Babizh\ ayev%20MA%22%5BAuthor%5D & itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.\ Pubmed_RVAbstract>, > *Yermakova VN*<http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed & Cmd=Search & Term=%22Yermak\ ova%20VN%22%5BAuthor%5D & itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.P\ ubmed_RVAbstract>, > *Semiletov YA*<http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed & Cmd=Search & Term=%22Semile\ tov%20YA%22%5BAuthor%5D & itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.P\ ubmed_RVAbstract>, > *Deyev AI*<http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed & Cmd=Search & Term=%22Deyev%\ 20AI%22%5BAuthor%5D & itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubme\ d_RVAbstract> > . > > Innovative Vision Products Inc., County of New Castle, Delaware 19810, > USA. > > The naturally occurring compound Nalpha-acetylcarnosine is proposed as a > prodrug of L-carnosine that is resistant to enzymatic hydrolysis by > carnosinase. Eyes of rabbits were treated with 1% Nalpha-acetylcarnosine, > L-carnosine, or placebo and extracts of the aqueous humor from the anterior > eye chamber were analyzed for imidazole content by reverse-phase analytical > high performance liquid chromatography (HPLC) and thin-layer (TLC) and > ion-exchange chromatographic techniques. Topical administration of pure > L-carnosine to the rabbit eye did not lead to accumulation of this compound > in the aqueous humor over 30 min in concentration exceeding that in the > placebo-treated matched eye. Nalpha-Acetylcarnosine showed dose-dependent > hydrolysis in its passage from the cornea to the aqueous humor, releasing > L-carnosine after l5-30 min of ocular administration of the prodrug in a > series of therapeutic modalities: instillation < or = subconjunctival > injection < or = ultrasound-induced phoresis. Different treatment techniques > showed excellent toleration of 1%Nalpha-acetylcarnosine by the eye. Once in > the aqueous humor, L-carnosine might act as an antioxidant and enter the > lens tissue when present at effective concentrations (5-l5 mM). The > advantage of the ophthalmic prodrug Nalpha-acetylcarnosine and its > bioactivated principle L-carnosine as universal antioxidants relates to > their ability to give efficient protection against oxidative stress both in > the lipid phase of biological membranes and in aqueous environments. > Nalpha-Acetylcarnosine is proposed for treatment of ocular disorders that > have a component of oxidative stress in their genesis (cataracts, glaucoma, > retinal degeneration, corneal disorders, ocular inflammation, complications > of diabetes mellitus, and systemic diseases). > > PMID: 10851037 [PubMed - indexed for MEDLINE] > ------------------------------ > *6: *J Control Release. <javascript:AL_get(this, 'jour', 'J Control > Release.');> 2000 Mar 1;65(1-2):1-11. > Related Articles<http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed & DbFrom=pubmed & Cmd=Li\ nk & LinkName=pubmed_pubmed & LinkReadableName=Related%20Articles & IdsFromResult=1069\ 9264 & ordinalpos=6 & itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_\ RVAbstract>, > Links <javascript:PopUpMenu2_Set(Menu10699264);> > [image: Click here to read]<http://www.ncbi.nlm.nih.gov/entrez/utils/fref.fcgi?PrId=3048 & itool=Abstrac\ t-def & uid=10699264 & db=pubmed & url=http://linkinghub.elsevier.com/retrieve/pii/S01\ 68365999002266> > *Meeting future challenges in topical ocular drug delivery: development of > an air-interfaced primary culture of rabbit conjunctival epithelial cells on > a permeable support for drug transport studies.* > > *Yang JJ*<http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed & Cmd=Search & Term=%22Yang%2\ 0JJ%22%5BAuthor%5D & itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed\ _RVAbstract>, > *Ueda H*<http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed & Cmd=Search & Term=%22Ueda%20\ H%22%5BAuthor%5D & itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_R\ VAbstract>, > *Kim K*<http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed & Cmd=Search & Term=%22Kim%20K\ %22%5BAuthor%5D & itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RV\ Abstract>, > *Lee VH*<http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed & Cmd=Search & Term=%22Lee%20\ VH%22%5BAuthor%5D & itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_\ RVAbstract> > . > > Department of Pharmaceutical Sciences, School of Pharmacy, University of > Southern California, 1985 Zonal Avenue, PSC 704, Los Angeles, CA, USA. > > The purpose of this study was to develop and characterize a functional > air-interfaced primary culture of rabbit conjunctival epithelial cells grown > on a permeable support for drug transport studies. Conjunctival epithelial > cells from the pigmented rabbit were isolated, seeded at 1.2 x 10(6) cells > cm(-2) on permeable Transwell filters, and cultured at the air interface > using a modified PC-1 medium. Conjunctival epithelial cell layers showed a > transepithelial resistance of 1.1+/-0.1 kOmega cm(2), a potential > difference of 17.0+/-0.5 mV, and an equivalent short-circuit current > (I(eq)) of 16.1+/-0.4 microA cm(-2). The I(eq) was reduced by 35% using > 0.01 mM bumetanide, 66% using 0.1 mM ouabain, 46% using 2 mM barium > chloride (all three in the basolateral fluid), and 63% using 0.3 mM NPAA > in the apical fluid, consistent with active Cl(-)-secretion across the > conjunctival epithelial barrier. Amiloride-sensitive Na(+) channels were > absent. The permeability of the cell layers to polar solutes decreased with > increased solute size, and the calculated equivalent pore size was about > 8.0 nm. The Papp of beta-blockers varied with lipophilicity in a sigmoidal > fashion. Uridine transport showed temperature sensitivity and > directionality, favoring transport in the apical-to-basolateral direction. > Apical L-carnosine uptake was reduced by 46% in the absence of an inwardly > directed proton gradient, and lowering the temperature to 4 degrees C > abolished direction-dependent L-carnosine uptake. Furthermore, uptake was > inhibited by 73% using apical 10 mM glycyl sarcosine (a dipeptide > transporter substrate) and by 60% using 1 mM L-valacyclovir (a dipeptide > prodrug). In conclusion, a functional air-interfaced primary culture of > rabbit conjunctival epithelial cell layers was established. This > air-interfaced primary culture model may be useful for studying passive and > active transport processes for ion and solute translocation in the mammalian > conjunctival epithelial barrier in a defined experimental setting. > > Publication Types: > > - Research Support, U.S. Gov't, P.H.S. <javascript:AL_get(this, > 'ptyp', 'Research Support, U.S. Gov\'t, P.H.S.');> > > > PMID: 10699264 [PubMed - indexed for MEDLINE] > ------------------------------ > *7: *J Mol Neurosci. <javascript:AL_get(this, 'jour', 'J Mol Neurosci.');>1998 Jun;10(3):193-208. > Related Articles<http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed & DbFrom=pubmed & Cmd=Li\ nk & LinkName=pubmed_pubmed & LinkReadableName=Related%20Articles & IdsFromResult=9770\ 642 & ordinalpos=7 & itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_R\ VAbstract>, > Links <javascript:PopUpMenu2_Set(Menu9770642);> > [image: Click here to read]<http://www.ncbi.nlm.nih.gov/entrez/utils/fref.fcgi?PrId=3055 & itool=Abstrac\ t-def & uid=9770642 & db=pubmed & url=http://dx.doi.org/10.1007/BF02761774> > *Function of the N-acetyl-L-histidine system in the vertebrate eye. > Evidence in support of a role as a molecular water pump.* > > *Baslow MH*<http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed & Cmd=Search & Term=%22Baslow\ %20MH%22%5BAuthor%5D & itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubm\ ed_RVAbstract> > . > > S. Kline Institute for Psychiatric Research, Center for > Neurochemistry, Orangeburg, NY, USA. > > N-acetyl-L-histidine (NAH) is a major constituent of poikilotherm brain, > eye, heart, and muscle, but for which there is no known function. NAH is > characterized by high tissue concentrations, a high tissue/extracellular > fluid (ECF) gradient, and by a continuous selective and regulated efflux > into ECF. In the eye, there is a complete compartmentalization of the > synthetic and hydrolytic enzymes, with synthesis of NAH from AcCoA and > L-histidine (His) occurring in the lens, and its hydrolysis to acetate and > His restricted to surrounding ocular fluids. Using 14C-isotopes, the cycling > of NAH between lens and ocular fluids in a simple support medium consisting > of NaCl (0.9%), Ca2+ (4 mEq/L) and D-glucose (5 mM) at pH 7.4 has > previously been observed. In the present study, using the isolated lens of > the goldfish eye, each of the components of that support medium has been > individually varied in order to determine its effect on NAH release down its > intercompartmental gradient. As a result of these and related studies, it is > suggested that NAH may function as a metabolically recyclable > gradient-driven molecular water pump. It is proposed that water influx or > generation of metabolic water serves as the trigger mechanism to open a > Ca-dependent gate for the release of NAH down its gradient, along with its > associated water. Preliminary analyses suggest that in addition to its > potential for multiple daily cycles, a strongly ionized hydrophilic > molecule, such as NAH, may include a large power function as a result of its > attraction to water, and it has been calculated that an aqua complex of each > NAH molecule may have 33 dipole-dipole-associated water molecules as it > passes into ECF. It is this unique combination of a capacity for multiple > cycles per day, coupled with a large power function, that may allow for such > an intracellular osmolyte to be present in relatively low concentration in > comparison to total cellular osmolality, and yet to perform a large and > important task with little expenditure of energy. With each NAH molecule > recycled up to 10 times/d, and a power factor of 33, there could be 330 mmol > of water transported/mmol of NAH each day. With typical NAH concentrations > in brains of poikilothermic vertebrates of 5-10 mmol/kg, there is the > potential for up to 3.3 mol (60 mL) of water to be removed each day/kg of > brain, a value that represents about 8% of total brain water content. > Dewatering of the released osmolyte would occur in two additional steps, > consisting of its hydrolysis and the subsequent active uptake of its > metabolites. It is also suggested that NAH is the archetype of several > metabolically and structurally related cellular osmolytes found in both > poikilotherms and homeotherms, for which there is similarly no known > function, and these may form a family of cycling hydrophilic osmolytes that > serve as molecular water pumps in a variety of tissues. These include the > basic His containing derivatives: NAH, carnosine, anserine, ophidine, and > homocarnosine, and the acidic aspartate derivatives: N-acetyl-L-aspartate > (NAA) and N-acetyl-L-aspartylglutamate (NAAG). In each of these cases, the > high intracellular/extracellular osmolyte gradient appears to be maintained > by combining a hydrophilic protein amino acid with a nonprotein moiety to > block its use in other intracellular metabolic pathways, and by blocking > catabolism of the derivative by maintaining its hydrolytic enzyme in an > extracytosolic membrane or extracellular compartment. Unlike other known > water-regulating mechanisms, the proposed cellular system is unique in that > as a water pump, it can function as a water regulator independently of > extracellular solute composition or osmolality. Finally, based on the > hypothesis developed, the NAH system would represent the first cellular > water pump to be identified. > > PMID: 9770642 [PubMed - indexed for MEDLINE] > ------------------------------ > *8: *Clin Chim Acta. <javascript:AL_get(this, 'jour', 'Clin Chim Acta.');>1996 Oct 15;254(1):1-21. > Related Articles<http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed & DbFrom=pubmed & Cmd=Li\ nk & LinkName=pubmed_pubmed & LinkReadableName=Related%20Articles & IdsFromResult=8894\ 306 & ordinalpos=8 & itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_R\ VAbstract>, > Links <javascript:PopUpMenu2_Set(Menu8894306);> > [image: Click here to read]<http://www.ncbi.nlm.nih.gov/entrez/utils/fref.fcgi?PrId=3048 & itool=Abstrac\ t-def & uid=8894306 & db=pubmed & url=http://linkinghub.elsevier.com/retrieve/pii/0009\ 898196063565> > Erratum in: > > - Clin Chim Acta 1997 Mar 18;259(1-2):199-201. > > > *N alpha-acetylcarnosine is a prodrug of L-carnosine in ophthalmic > application as antioxidant.* > > *Babizhayev MA*<http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed & Cmd=Search & Term=%22Babizh\ ayev%20MA%22%5BAuthor%5D & itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.\ Pubmed_RVAbstract>, > *Yermakova VN*<http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed & Cmd=Search & Term=%22Yermak\ ova%20VN%22%5BAuthor%5D & itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.P\ ubmed_RVAbstract>, > *Sakina NL*<http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed & Cmd=Search & Term=%22Sakina\ %20NL%22%5BAuthor%5D & itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubm\ ed_RVAbstract>, > *Evstigneeva RP*<http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed & Cmd=Search & Term=%22Evstig\ neeva%20RP%22%5BAuthor%5D & itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel\ ..Pubmed_RVAbstract>, > *Rozhkova EA*<http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed & Cmd=Search & Term=%22Rozhko\ va%20EA%22%5BAuthor%5D & itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pu\ bmed_RVAbstract>, > *Zheltukhina GA*<http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed & Cmd=Search & Term=%22Zheltu\ khina%20GA%22%5BAuthor%5D & itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel\ ..Pubmed_RVAbstract> > . > > Moscow Helmholtz Research Institute of Eye Diseases, Russian Federation. > > The naturally occurring compound N alpha-acetylcarnosine (NAC) is proposed > as the prodrug of L-carnosine © resistant to enzymatic hydrolysis by human > serum carnosinase. Rabbit eyes were treated with 1% NAC, C or placebo and > extracts of the aqueous humor from the anterior eye chamber were analyzed > for imidazole content by reverse phase analytical high performance liquid > chromatography (HPLC), thin-layer (TLC) and ion-exchange chromatographic > techniques. The topical administration of pure C to the rabbit eye did not > lead to accumulation of this compound in the aqueous humor over 30 min in > concentration exceeding that in the placebo-treated matched eye. NAC showed > dose-dependent hydrolysis in its passage from the cornea to the aqueous > humor, releasing C after 15. 30 min of ocular administration of prodrug in a > series of therapeutical modalities: instillation < or = subconjunctival > injection < or = ultrasound induced phoresis. Different treatment techniques > showed excellent toleration of 1% NAC by the eye. Once in the aqueous humor, > C might act as an antioxidant and enter the lens tissue when present at > effective concentrations (5-15 mmol/l). The advantage of the ophthalmic > prodrug NAC and its bioactivated principle C as universal antioxidants > relates to their ability to give efficient protection against oxidative > stress both in the lipid phase of biological membranes and in an aqueous > environment. NAC is proposed to treat ocular disorders which have the > component of oxidative stress in their genesis (cataracts, glaucoma, retinal > degeneration, corneal disorders, ocular inflammation, complications of > diabetes mellitus, systemic diseases). > > PMID: 8894306 [PubMed - indexed for MEDLINE] > ------------------------------ > *9: *Biull Eksp Biol Med. <javascript:AL_get(this, 'jour', 'Biull Eksp > Biol Med.');> 1988 Apr;105(4):451-3. > Related Articles<http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed & DbFrom=pubmed & Cmd=Li\ nk & LinkName=pubmed_pubmed & LinkReadableName=Related%20Articles & IdsFromResult=3359\ 028 & ordinalpos=9 & itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_R\ VAbstract>, > Links <javascript:PopUpMenu2_Set(Menu3359028);> > > *[Effect of carnosine on intraocular pressure]* > > [Article in Russian] > > *Ermakova VN*<http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed & Cmd=Search & Term=%22Ermako\ va%20VN%22%5BAuthor%5D & itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pu\ bmed_RVAbstract>, > *Babizhaev MA*<http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed & Cmd=Search & Term=%22Babizh\ aev%20MA%22%5BAuthor%5D & itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.P\ ubmed_RVAbstract>, > *Bunin AIa*<http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed & Cmd=Search & Term=%22Bunin\ %20AIa%22%5BAuthor%5D & itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pub\ med_RVAbstract> > . > > It has been demonstrated in experiments on non-anesthetized rabbits that > conjunctival injection of carnosine (beta-alanyl 1-histidine) caused a > decrease in normal intraocular pressure and reduced prostaglandin-induced > ocular hypertension. The rapid onset of the pressure response and the > absence of papillary dilation in rabbits treated with carnosine were > observed. It is concluded that L-carnosine can be used as a potent drug for > the prevention of reactive hypertension syndrome. > > Publication Types: > > - English Abstract <javascript:AL_get(this, 'ptyp', 'English > Abstract');> > > > PMID: 3359028 [PubMed - indexed for MEDLINE] > ------------------------------ > *10: *Comp Biochem Physiol B. <javascript:AL_get(this, 'jour', 'Comp > Biochem Physiol B.');> 1978;61(2):253-8. > Related Articles<http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed & DbFrom=pubmed & Cmd=Li\ nk & LinkName=pubmed_pubmed & LinkReadableName=Related%20Articles & IdsFromResult=3183\ 74 & ordinalpos=10 & itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_R\ VAbstract>, > Links <javascript:PopUpMenu2_Set(Menu318374);> > > *Similarity of tuna N-acetylhistidine deacetylase and cod fish anserinase. > * > > *Lenney JF*<http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed & Cmd=Search & Term=%22Lenney\ %20JF%22%5BAuthor%5D & itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubm\ ed_RVAbstract>, > *Baslow MH*<http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed & Cmd=Search & Term=%22Baslow\ %20MH%22%5BAuthor%5D & itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubm\ ed_RVAbstract>, > *Sugiyama GH*<http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed & Cmd=Search & Term=%22Sugiya\ ma%20GH%22%5BAuthor%5D & itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pu\ bmed_RVAbstract> > . > > Department of Pharmacology, A. Burns School of Medicine, University > of Hawaii, Honolulu 96822. > > 1. The brain and ocular fluid of skipjack tuna (Katsuwonus pelamis) > contained high levels of N-acetylhistidine deacetylase. 2. This enzyme had a > molecular weight of about 120,000 and was activated by zinc or cobaltous > ions. 3. Cod (Gadus callarias) brain, ocular fluid and muscle contained a > similar metal-activated thiol hydrolase, the muscle enzyme being known as > anserinase. 4. The purified enzymes hydrolyzed N-acetylhistidine, carnosine, > homocarnosine, anserine and certain other dipeptides. 5. Their specificity > resembled that of hog kidney homocarnosinase. 6. In both fish, brain and > ocular fluid were rich sources of this hydrolase, whereas muscle contained > only trace amounts. > > Publication Types: > > - Comparative Study <javascript:AL_get(this, 'ptyp', 'Comparative > Study');> > - Research Support, U.S. Gov't, P.H.S. <javascript:AL_get(this, > 'ptyp', 'Research Support, U.S. Gov\'t, P.H.S.');> > > > PMID: 318374 [PubMed - indexed for MEDLINE] > ------------------------------ > __._, > Quote Link to comment Share on other sites More sharing options...
Guest guest Posted February 10, 2008 Report Share Posted February 10, 2008 My mother had a blocked eye duct. She had problems getting proper medical help with hers as well. She used as hot as she could stand, wet wash cloths for relief. > > well, I took the antibacterial eye drops and rills for 5 days like a > good little girl and it made the fog(infection in the aqueous humor > fluid) much worse not to mention my migraines,ect. a little better > now. I went to follow up with a doctor who than gave me a > prescription for...., you guessed it. more antibiotics. > pretty insane when you have better luck doctoring yourself and > practiceing advoidance than from a ER or doctors office. > whats bad is I still have blocked tear ducts and it well probibly > happen again with the next round of cns infection. > > Quote Link to comment Share on other sites More sharing options...
Guest guest Posted February 10, 2008 Report Share Posted February 10, 2008 yes, that what they told me at the hospital to do, I did a few days, than ,because I have found that for the migraines that are caused from cns fungal infections are helped best by useing a cold towel around the head, I went back to doctoring myself as usual. because I have found the fungal infections in the body can be helped by cold. the colder the better. for mine anyway. I do believe they knew more about this in the old days and maybe knew that infections that were fungal respond better to cold than heat. fungus thrives in heat.around my whole eye area was hot the hor washrags made it worse not better. just like the antibiotics made it worse, not better. there is actually some info. out there where their trying to develope a therostat type device to put in the head for cooling the head when people suffer from reaccuring cns infection and brain swelling (hydrosyphalitis)spelling. when your head is hot with migraines from cns fungal infections, for me cold is what helps. also have found that when my back side is burning from this(usually before it goes to my head) a cold towel on my back can sometimes mellow it out before it gets worse. maybe not the best way to control reaccuring fungal infections but when you cant get a doctor to even say the word, you have to than be your own doctor. I tottally beleave that reaccuring fungal infections can lead to cancer and have to do what I can to sloe that from happening. > > My mother had a blocked eye duct. She had problems getting proper > medical help with hers as well. She used as hot as she could stand, > wet wash cloths for relief. > > Quote Link to comment Share on other sites More sharing options...
Guest guest Posted February 10, 2008 Report Share Posted February 10, 2008 thanks Live, your talking about NAC? been there done that, me and herbs dont get along well, maybe it's because of all the allergies I now have. my " expert on toxic mold " first lawyer sent me to a herb doctor, said he would do the blood tests for mycotoxins(not), said he would be a expert witness in court (not) I have no further comment on that at this time. Quote Link to comment Share on other sites More sharing options...
Recommended Posts
Join the conversation
You are posting as a guest. If you have an account, sign in now to post with your account.
Note: Your post will require moderator approval before it will be visible.